Purchases through the above links give commission which helps fund this website
Recent literature: Phosphodiesterase-4 inhibitor
Date Journal Article title
2019 Apr J Surg Res Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
2019 Apr Expert Opin Pharmacother Evaluating crisaborole as a treatment option for atopic dermatitis.
2019 Exp Ther Med Phosphodiesterase 4 inhibitor plus metformin is erior to metformin alone for the treatment of polycystic ovary syndrome: A rat model study.
2019 Apr J Dermatol Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
2019 Apr Hautarzt [Gastrointestinal side effects of apremilast : Characterization and management].
2019 Apr J Dermatolog Treat Off-label studies on apremilast in dermatology: a review.
2019 Mar Acta Derm Venereol Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
2019 Apr Life Sci Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMPCREBTLR4 inflammatory and fibrogenic pathways.
2019 Biochem Pharmacol The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
2019 Ther Adv Musculoskelet Dis IL-12IL-23p40 identified as a downstream target of apremilast in iex vivoi models of arthritis.
2019 Mar Neurosci Res Adolescent psychosocial stress enhances sensitization to cocaine exposure in genetically vulnerable mice.
2019 Apr Eur J Med Chem Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
2019 Feb Free Radic Biol Med Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP+-induced oxidative insult.
2019 Feb J Drugs Dermatol Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
2019 Biochem Pharmacol FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemiareperfusion injury through activation of the AKTGSK3β β-catenin signaling pathway.
2019 Jan Neurobiol Aging Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
2019 Indian Dermatol Online J Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
2019 Feb J Am Acad Dermatol A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real life setting: data from the Leeds Combined Psoriatic Service.
2019 Apr Am J Physiol Lung Cell Mo... Extracellular vesicles: another compartment for the second messenger, cyclic adenosine monophosphate.
2019 Hum Exp Toxicol Roflumilast, a phosphodiesterase 4 inhibitor, attenuates cadmium-induced renal toxicity via modulation of NF-κB activation and induction of NQO1 in rats.
2019 Apr Eur J Pharmacol TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
2019 Jan BMJ Case Rep Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.
2019 Dermatol Ther (Heidelb) Tolerability of Topical Treatments for Atopic Dermatitis.
2018 Pharm Pat Anal Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE34 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
2019 J Med Econ Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
2019 Mol Med Rep Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B.
2019 Ann Rheum Dis Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.
2019 Metab Brain Dis Roflumilast ameliorates cognitive impairment in APPPS1 mice via cAMPCREBBDNF signaling and anti-neuroinflammatory effects.
2018 Dec Physiol Res Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury.
2018 Drug Des Devel Ther Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers.
2018 Dec Psychopharmacology (Berl) An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
2019 J Am Acad Dermatol Apremilast for moderate hidradenitis purativa: Results of a randomized controlled trial.
2018 J Manag Care Spec Pharm Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
2018 Nov Arthritis Rheumatol Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis.
2018 Arerugi
2018 Int J Chron Obstruct Pulm... Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
2019 Arch Dermatol Res A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in jects with moderate-to-severe alopecia areata.
2018 Nov Int J Mol Sci Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.
2018 Dec Biochem Biophys Res Commun Compound D159687, a phosphodiesterase 4D inhibitor, induces weight and fat mass loss in aged mice without changing lean mass, physical and cognitive function.
2018 Innate Immun Synergistic effect of phosphodiesterase 4 inhibitor and serum on migration of endotoxin-stimulated macrophages.
2019 Feb Int J Neuropsychopharmacol Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors and Prevents Dendritic Spine Loss in Mice Hippocampi.
2019 J Am Acad Dermatol A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor.
2019 Mar Prog Neuropsychopharmacol... FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress.
2018 Oct J Matern Fetal Neonatal Med The phosphodiesterase-4 inhibitor Rolipram promotes cognitive function recovery in prenatal Escherichia coli infected offspring.
2018 Dermatol Ther (Heidelb) Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.
2018 Nov J Dermatolog Treat Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
2019 Exp Dermatol The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
2018 Int Immunopharmacol Potent immunopressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction.
2018 Dec JAMA Dermatol Treatment of Severe Hailey-Hailey Disease With Apremilast.
2018 J Biochem Mol Toxicol p-Hydroxybenzyl alcohol inhibits four obesity-related enzymes in vitro.
2018 Nov J Dermatolog Treat Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis.
2018 Oct Eur J Med Chem Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE47 inhibitors: A new approach for the treatment of pain.
2019 G Ital Dermatol Venereol Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
2018 Sep Aging (Albany NY) Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder.
2018 Lancet Respir Med Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
2018 J Dermatol Real-world use of apremilast for patients with psoriasis in Japan.
2018 Neuropsychopharmacology Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice.
2018 Aug J Drugs Dermatol Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
2018 Drug Des Devel Ther Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.
2018 Front Aging Neurosci Inhibition of Phosphodiesterase-4 Reverses Aβ-Induced Memory Impairment by Regulation of HPA Axis Related cAMP Signaling.
2018 Front Immunol Apremilast Ameliorates Experimental Arthritis iviai Suppression of Th1 and Th17 Cells and Enhancement of CD4+Foxp3+ Regulatory T Cells Differentiation.
2018 Psoriasis (Auckl) Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives.
2018 Sep Biochem Biophys Res Commun Glucocorticoid-induced CREB activation and myostatin expression in C2C12 myotubes involves phosphodiesterase-34 signaling.
2018 Oct Org Biomol Chem Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors.
2018 RMD Open Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
2018 Nihon Yakurigaku Zasshi [In vivo analysis for mechanism of drug action by juxtacellular recording].
2018 Jun Antibiotics (Basel) Lysoquinone-TH1, a New Polyphenolic Tridecaketide Produced by Expressing the Lysolipin Minimal PKS II in iStreptomyces albusi.
2018 Physiol Rep Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury.
2018 Nov Acta Derm Venereol A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
2018 Sep Eur J Pharm Sci Design and characterization of emulsified spray dried alginate microparticles as a carrier for the dually acting drug roflumilast.
2018 Tuberc Respir Dis (Seoul) Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study.
2018 Jun FASEB J Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration.
2018 Aug Eur J Pharmacol Effect of co-administration of two different phosphodiesterase inhibitors and a β3-adrenoceptor agonist in an experimental model of detrusor overactivity.
2018 Jun Bioanalysis Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MSMS and its application to a PK study.
2019 J Dermatolog Treat Treatment of psoriasis with crisaborole.